{rfName}

Indexed in

Citations

4

Altmetrics

Analysis of institutional authors

Rodriguez-Espinosa, DianaAuthorJesus Broseta, JoseAuthorIsabel Alvarez-Mora, MariaAuthorNicolau, CarlosAuthorQuintana, Luis FAuthorPineiro, Gaston JAuthorPoch, EstebanAuthorBlasco, MiquelCorresponding Author

Share

November 27, 2023
Publications
>
Article
No

Creatine Kinase Elevation in Autosomal Dominant Polycystic Kidney Disease Patients on Tolvaptan Treatment

Publicated to: NEPHRON. 147 (3-4): 152-157 - 2023-04-01 147(3-4), DOI: 10.1159/000526368

Authors:

Rodriguez-Espinosa, Diana; Jesus Broseta, Jose; Bastida, Carla; Isabel Alvarez-Mora, Maria; Nicolau, Carlos; Alvarez, Cristina; Agraz-Pamplona, Irene; Sanchez-Baya, Maya; Furlano, Monica; Ruiz, Cesar; Quintana, Luis F; Pineiro, Gaston J; Poch, Esteban; Torra-Balcells, Roser; Blasco, Miquel
[+]

Affiliations

Hosp Clin Barcelona, Dept Biochem & Mol Genet, Barcelona, Spain - Author
Hosp Clin Barcelona, Dept Pharm, Barcelona, Spain - Author
Hosp Clin Barcelona, Diagnost Imaging Ctr, Genito Urinary Dept, Barcelona, Spain - Author
Univ Autonoma Barcelona, Dept Nephrol, Fundacio Puigvert, IIB St Pau, Barcelona, Spain - Author
Univ Barcelona, Hosp Clin, Ctr Referencia Enfermedad Glomerular Compleja Sis, Nephrol & Kidney Transplantat Dept, Barcelona, Spain - Author
Vall dHebron Univ Hosp, Dept Nephrol, Barcelona, Spain - Author
See more

Abstract

Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary cause of end-stage kidney disease. Currently, tolvaptan is the only treatment that has proven to delay disease progression. The most notable side effect of this therapy is drug-induced liver injury; however, recently, there have been two reports of creatine kinase (CK) elevation in ADPKD patients on tolvaptan treatment. We set out to monitor and determine the actual incidence of CK elevation and evaluate its potential association with other clinical factors. Methods: This is an observational retrospective multicenter study performed in rapidly progressive ADPKD patients on tolvaptan treatment from Barcelona, Spain. Laboratory tests, demographics, treatment dose, and reported symptoms were collected from October 2018 to March 2021. Results: Ninety-five patients initiated tolvaptan treatment during follow-up. The medication had to be discontinued in 31 (32.6%) patients, primarily due to aquaretic effects (12.6%), elevated liver enzymes (8.4%), and symptomatic or persistently elevated CK levels (3.2%). Moreover, a total of 27 (28.4%) patients had elevated CK levels, with most of them being either transient (12.6%), mild and asymptomatic (4.2%), or resolved after dose reduction (3.2%) or temporary discontinuation (2.1%). Conclusion: We pre-sent the largest cohort that has monitored CK levels in a real-life setting, finding them elevated in 28.4% of patients. More research and monitoring will help us understand the clinical implications and the pathophysiological mechanism of CK elevation in this population.
[+]

Keywords

adpkdcreatine-kinaseside effectCreatine-kinase,tolvaptan,adpkd,side effecTolvaptan

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal NEPHRON due to its progression and the good impact it has achieved in recent years, according to the agency Scopus (SJR), it has become a reference in its field. In the year of publication of the work, 2023, it was in position , thus managing to position itself as a Q1 (Primer Cuartil), in the category Urology.

Independientemente del impacto esperado determinado por el canal de difusión, es importante destacar el impacto real observado de la propia aportación.

Según las diferentes agencias de indexación, el número de citas acumuladas por esta publicación hasta la fecha 2026-04-04:

  • WoS: 2
[+]

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2026-04-04:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 8.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 8 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 10.
  • The number of mentions on the social network X (formerly Twitter): 9 (Altmetric).
[+]

Leadership analysis of institutional authors

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (Rodriguez Espinoza, Diana María) and Last Author (Blasco Pelicano, Miquel).

the author responsible for correspondence tasks has been Blasco Pelicano, Miquel.

[+]